[8-K] Haemonetics Corporation Reports Material Event

Rhea-AI Filing Summary

On 14 Jul 2025, HA Sustainable Infrastructure Capital, Inc. (HASI) filed an 8-K announcing the appointment of Nitya Gopalakrishnan, 53, as Executive Vice President & Chief Operating Officer.

Gopalakrishnan joins from BlackRock, where she most recently served as Managing Director & Head of Investment Infrastructure, SMA Solutions, following 25 years in senior platform, engineering and COO roles. The filing states there are no related-party relationships or transactions requiring disclosure.

The offer letter sets a $400 k base salary, target annual cash bonus equal to 125 % of salary, and a 20,000-share restricted-stock sign-on grant vesting over three years. She is also eligible for annual LTIP awards (~100 % of salary) and up to $100 k relocation reimbursement.

If terminated without cause, severance includes 12-months salary, an average prior-bonus payout, one year of health benefits, and full acceleration of all unvested equity.

No other material events, financial results, or transactions were disclosed.

Positive

• High-caliber hire from BlackRock brings 25 years of platform and infrastructure experience that could improve operational execution and scalability.
• Clear compensation disclosure enhances transparency and aligns incentives through a mix of cash and equity.

Negative

• Generous single-trigger severance includes full equity acceleration, potentially increasing future expense and shareholder dilution upon termination.
• Additional fixed costs (salary, relocation) add to G&A, though impact is minor relative to company size.

Insights

Corporate Governance Specialist

TL;DR: Strategic COO hire adds BlackRock pedigree; compensation typical, severance generous but not unusual—overall governance-neutral.

HASI strengthens its C-suite by recruiting an executive with deep operational and platform-integration expertise from BlackRock. The disclosed pay mix—base, bonus, equity, LTIP—is broadly market-aligned for a mid-cap infrastructure REIT. The single-trigger acceleration of equity on a without-cause termination is shareholder-friendly for retention but slightly rich compared with double-trigger norms. No related-party concerns or governance red flags emerge. Impact on governance outlook: neutral.

Equity Analyst

TL;DR: Leadership upgrade may aid execution; financial impact immaterial, share count dilution negligible.

The hire should bolster operational scale as HASI grows its sustainable-asset portfolio. Direct cash cost (~$0.4 m salary plus variable comp) is minimal relative to HASI’s ~$200 m annual G&A. The 20,000 restricted shares equate to <0.02 % of outstanding—immaterial dilution. Severance obligations introduce limited contingent liability. Because no earnings or guidance were provided, the announcement is strategically positive but not immediately valuation-moving.

0000313143false00003131432025-07-242025-07-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 24, 2025

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

001-14041

04-2882273

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

125 Summer Street

Boston, MA 02110

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $.01 par value per share			HAE			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2025 Annual Meeting of Shareholders of Haemonetics Corporation (the “Company”) was held on Thursday, July 24, 2025. Of the 48,041,228 shares outstanding and entitled to vote at the meeting, 45,613,041 shares were represented at the meeting, constituting a quorum of 94.95%.

The results of the votes for each proposal considered at the meeting are set forth below:

1. The shareholders elected each of Christopher A. Simon, Robert E. Abernathy, Diane M. Bryant, Michael J. Coyle, Charles J. Dockendorff, Lloyd E. Johnson, Mark W. Kroll, Claire Pomeroy and Ellen M. Zane as directors for one-year terms expiring in 2026 based upon the following votes:

Nominees						For						Withhold						Broker Non-Votes
Christopher A. Simon						43,756,151						99,166						1,757,724
Robert E. Abernathy						43,061,317						794,000						1,757,724
Diane M. Bryant						43,568,258						287,059						1,757,724
Michael J. Coyle						43,670,835						184,482						1,757,724
Charles J. Dockendorff						42,588,774						1,266,543						1,757,724
Lloyd E. Johnson						43,151,041						704,276						1,757,724
Mark W. Kroll						42,739,455						1,115,862						1,757,724
Claire Pomeroy						43,567,795						287,522						1,757,724
Ellen M. Zane						43,066,065						789,252						1,757,724

2. The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers based upon the following votes:

For						Against						Abstain						Broker Non-Votes
43,016,961						585,626						252,730						1,757,724

3. The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 28, 2026 based upon the following votes:

For						Against						Abstain
43,843,396						1,525,114						244,531

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

July 25, 2025

By:

/s/ Christopher A. Simon

Name:

Christopher A. Simon

Title:

President and Chief Executive Officer

FAQ

Who was appointed COO of HASI on July 14, 2025?

HASI appointed Nitya Gopalakrishnan, formerly a Managing Director at BlackRock, as Executive Vice President & Chief Operating Officer.

What is the new COO’s base salary and bonus potential at HASI?

The offer letter sets a $400,000 base salary with a target annual cash bonus equal to 125 % of salary.

How many restricted shares will the new HASI COO receive as a sign-on grant?

She will receive 20,000 restricted shares of HASI common stock, vesting annually over three years.

What severance benefits are provided if the HASI COO is terminated without cause?

Benefits include 12-months salary, average prior bonus, one year of health coverage, and immediate vesting of all unvested equity.

Does the 8-K disclose any related-party transactions involving the new COO?

No. The filing explicitly states there are no related-party relationships or transactions requiring disclosure.